Solstice Advanced Materials Inc. (SOLS) | The Buildout — AI Infrastructure
The Verdict
Solstice Advanced Materials operates across seven businesses spanning refrigerants, nuclear conversion, semiconductor materials, and specialty chemicals. Its copper manganese sputtering targets are used in the most advanced semiconductor nodes for AI and high‑performance computing; its HFO‑based refrigerants cool the data centres that house those chips; and its uranium hexafluoride conversion business — the sole U.S. provider — supplies nuclear fuel for the power plants increasingly needed to meet AI‑driven electricity demand. These three secular threads tie the company directly to the AI infrastructure build‑out, even though AI‑linked revenue remains a minority of sales today.
| Market Cap | — |
| Revenue (TTM) | $4.1B |
| Revenue Growth | +9.2% |
| EBITDA Margin (TTM) | 22.3% |
| Net Debt | $1.7B |
| Earnings Beats | 1 of 3 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Electronic Materials demand is supply‑constrained: the company is “selling everything it can make” in sputtering targets and has begun initial discussions for a second expansion beyond the $200M doubling.
- Nuclear conversion services grew 27% y/y in Q2 and signed three SMR supply agreements, with an engineering study underway for a major capacity expansion.
- Refrigerants for data‑centre cooling is the fastest‑growing part of the refrigerants business, growing “strong double digits,” with two‑phase direct‑to‑chip cooling in the pipeline.
- Management raised full‑year 2026 guidance to $4.125–$4.185B in sales and $1.035–$1.055B in adjusted EBITDA, after a pattern of under‑promising and delivering beats.
- The pending Element Solutions acquisition is explicitly intended to increase exposure to high‑growth electronics and AI infrastructure, potentially tilting the portfolio further toward secular tailwinds.
What We’re Watching
- RAS margins fell 648 bps y/y in Q2; the mid‑30% H2 margin target depends on the HFO aftermarket “kicking in” — if that timing slips, the margin recovery could stall.
- Chemours, a refrigerant competitor, warned of decelerating HFO‑driven growth in 2H 2026 from tough comps, which could also affect Solstice’s Refrigerants volumes.
- The $30M nuclear product‑loan return in 2H, weighted to Q4, will mask underlying Nuclear revenue growth and segment margin.
- The Pomerantz LLP investigation, announced July 30, 2026, is an unknown risk; any escalation into litigation could cause management distraction.
The thesis is strengthening: secular demand across semiconductor materials, nuclear fuel, and data‑center refrigerants is translating into double‑digit growth, and capacity expansions are being accelerated to meet it. The margin recovery, however, is still a promise — hinging on the HFO aftermarket and the timely ramp of Spokane. The open question is whether management can convert its strong volume momentum into sustained margin expansion while navigating the transformational Element Solutions acquisition.
Earnings
Q2 FY2026 revenue rose 11% y/y to $1,148 million, exceeding the top end of guidance, while adjusted EBITDA of $290 million (+2% y/y) produced a margin of 25.3%. Six of seven businesses grew, with Electronic Materials and Nuclear each posting double‑digit gains despite capacity constraints.
| Metric | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $1.1B | $991M | $1.0B | +11.1% |
| Gross margin | 32.2% | 31.9% | 34.6% | -240bps |
| EBITDA | $279M | $239M | $274M | +1.8% |
| EPS | $0.75 | $0.53 | $0.10 | +640.9% |
For the first time in decades, we are seeing meaningful innovation from entrepreneurs across the nuclear ecosystem.— David Sewell, CEO, July 30, 2026
Management tone: Management’s tone on the Q2 call was confident and execution‑focused, extending the conservative‑guidance‑and‑beat pattern established in Q1. The team openly attributed the RAS margin decline to transitory turnarounds, walked through the nuclear expansion engineering study, and declined to break out data‑centre refrigerant size, citing competitive sensitivity — a consistent, if mildly guarded, approach.
Management Guidance
Management raised full‑year 2026 guidance to net sales of $4.125–$4.185 billion, adjusted EBITDA of $1.035–$1.055 billion, and adjusted diluted EPS of $2.75–$2.95. Q3 2026 net sales were guided to $990 million–$1.03 billion with an implied adjusted EBITDA margin in the low‑25% range. The raise reflects strong H1 execution and continued momentum, though the company acknowledged that an uncertain macroeconomic backdrop and pending nuclear loan‑return drag remain.
Trajectory
Revenue recovered from a period of stagnation with a 15.8% sequential jump in Q2 FY2026 to $1,148 million, the highest quarterly run‑rate in the two‑year trailing record. Gross margin has stabilized at 32.2%, while EBITDA margin expanded 20bps sequentially behind operating leverage and the normalization of noncontrolling interest. The trajectory is one of accelerating top‑line growth, supported by nuclear, semiconductor, and data‑centre demand, but the margin path remains dependent on the HFO aftermarket and the ramp of Spokane capacity.
The Model
The model projects FY+1 revenue of $4,160 million and EBITDA of $1,098 million (26.4% margin), followed by FY+2 revenue of $4,580 million and EBITDA of $1,296 million (28.3% margin). The near‑term forecast is anchored by capacity‑constrained Electronic Materials growth, nuclear debottlenecking, and the HFO transition, while FY+2 assumes incremental output from the Spokane expansion and the start of the HFO aftermarket contributing to margin expansion.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $3.9B | $4.2B | $4.6B |
| YoY Growth | — | +7.1% | +10.1% |
| EBITDA | $931M | $1.1B | $1.3B |
| EBITDA Margin | 24.0% | 26.4% | 28.3% |
Projections are the median of 5 independent model runs. The model’s revenue sits 6.0% above analyst consensus.
Management raised full‑year 2026 guidance to net sales of $4.125–$4.185 billion, adjusted EBITDA of $1.035–$1.055 billion, and adjusted diluted EPS of $2.75–$2.95. Q3 2026 net sales were guided to $990 million–$1.03 billion with an implied adjusted EBITDA margin in the low‑25% range. The raise reflects strong H1 execution and continued momentum, though the company acknowledged that an uncertain macroeconomic backdrop and pending nuclear loan‑return drag remain.
What Could Go Right — and Wrong
- The HFO aftermarket materializes in late 2026 or 2027, lifting RAS margins to mid‑30s% and demonstrating a sustainable structural improvement.
- The nuclear expansion engineering study yields a decision to build a major new conversion facility with long‑term customer commitments, extending the sole‑source position into the 2030s.
- Spokane output ramps faster than planned and a second expansion is announced within 12 months, confirming that sputtering‑target demand outpaces the initial doubling.
- The Element Solutions acquisition closes on schedule and integration proceeds smoothly, accelerating the portfolio’s pivot toward electronics and AI infrastructure without straining leverage targets.
- Next‑gen yf molecule achieves qualification wins with key data‑center customers, opening a new product cycle before the current HFO cycle peaks.
- The HFO aftermarket fails to develop, keeping RAS margins in the high‑20s% range, and the mid‑30% target is missed.
- The nuclear expansion study concludes that a major new facility is not viable without substantial government subsidies, deferring the capacity cycle.
- Semiconductor demand softens and the Spokane expansion comes online just as sputtering‑target orders weaken, turning a capacity‑constrained growth story into an over‑investment problem.
- The Pomerantz investigation escalates into a securities class action, distracting management and imposing legal costs.
- The Element Solutions acquisition encounters antitrust delays or financing difficulties, pushing the close beyond 1H 2027 and raising leverage above anticipated levels.
Looking Ahead
The next twelve months will test whether Solstice can convert tight supply and secular demand into sustained margin expansion. The nuclear expansion study, expected later this year, could set the stage for a multi‑year capacity cycle; in the nearer term, the Q3 RAS segment margin will be the first hard check on the promised mid‑30% H2 exit rate. Meanwhile, the Element Solutions acquisition is expected to close in 1H 2027, potentially reshaping the company’s growth and leverage profile.
- Q3 2026RAS segment margin check — The Q3 print will reveal whether the mid‑30% H2 margin target is within reach after the Q2 turnaround trough.
- H2 2026Spokane capacity ramp begins — Revenue contribution from the expanded sputtering-target capacity should become visible in Electronic Materials.
- Later 2026Nuclear expansion decision — Management expects to share the outcome of the engineering study — a major capacity commitment or a smaller debottlenecking.
- Later 2026Metropolis debottlenecking update — Expect a formal increase beyond 10,000 metric tons; customer contracts may follow.
- 1H 2027Element Solutions close — Transaction closure would accelerate AI‑infrastructure exposure and test financing and deleveraging targets.
Financials
Annual Summary
| Metric | FY2025 | TTM |
|---|---|---|
| Revenue | $3.9B | $4.1B |
| Gross Margin | 32.1% | 30.6% |
| EBITDA | $931M | $2.2B |
| EBITDA Margin | 24.0% | 22.3% |
| Net Income | $156M | $210M |
| Free Cash Flow | $91M | $982M |
| Net Cash | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)30.6%
- EBITDA Margin (TTM)22.3%
- Net Margin (TTM)5.1%
- ROIC16.8%
- FCF Conversion43.0%
- SBC / Revenue0.2%
The Company
Solstice Advanced Materials was spun out of Honeywell in late 2025 and operates seven businesses across two segments: Refrigerants & Applied Solutions (RAS) and Electronic & Specialty Materials (ESM). The RAS segment includes refrigerants, nuclear conversion, building solutions, and healthcare packaging; ESM encompasses electronic materials (sputtering targets, thermal interface materials, heat spreaders), safety and defense fibers, and research chemicals. The company’s brands include Solstice, Genetron, Aclar, and Spectra.
The company runs 20 manufacturing sites globally — 16 in the Americas, 3 in Asia Pacific, and 1 in EMEA. It is the sole U.S. provider of uranium hexafluoride (UF₆) conversion through its ConverDyn joint venture with General Atomics, and its Spokane, Washington facility produces copper manganese sputtering targets that are qualified at leading‑edge semiconductor nodes. Vertical integration varies by business: nuclear conversion is an asset‑heavy conversion facility, while some refrigerants are produced through joint ventures and supply chain partnerships.
Business Segments
Competitive Landscape
Solstice competes with Arkema, Chemours, Daikin, and Orbia in refrigerants, where the HFO transition is reshaping the field. In nuclear conversion, the ConverDyn joint venture holds a sole‑source position in the U.S. — a near‑irreplaceable advantage given the 60‑year operating history and high regulatory barriers. In electronic materials, copper manganese targets have become “the go‑to product for leading‑edge nodes,” although other suppliers exist; the company’s qualification at advanced nodes and top supplier award from SK Hynix suggest a performance edge.
- ChemoursThermal & Specialized Solutions segment grew 22% with record margins; warned of decelerating HFO growth in 2H 2026.
- ArkemaNamed as a competitor in 10‑K; not discussed in detail.
- DaikinNamed as a competitor in 10‑K; not discussed in detail.
- OrbiaNamed as a competitor in 10‑K; not discussed in detail.
Supply Chain
Solstice sits between raw‑material suppliers (sulfur, precious metals) and a range of end‑markets: semiconductor fabricators, nuclear utilities, data‑center operators, and pharmaceutical packaging firms. The company is the sole U.S. UF₆ converter and a key supplier of sputtering targets to advanced chipmakers.
More on SOLS: Earnings recap